Tokyo, Japan

Kozo Hiratsuka

This inventor holds 1 USPTO granted patent. Top assignee: Mitsubishi-Tokyo Pharmaceuticals, Inc.. Active years: 2000.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Kozo Hiratsuka. Retrieved from https://idiyas.com/inventor/kozo-hiratsuka-vsql4n0e

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile


% Patents Active = 100.0

Average Co-Inventor Count = 7.0

ph-index = 1

Forward Citations = 22(Granted Patents)


Company Filing History:


Years Active: 2000

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Kozo Hiratsuka: Innovator in Pharmaceutical Compounds

Introduction

Kozo Hiratsuka is a prominent inventor based in Tokyo, Japan. He has made significant contributions to the field of pharmaceuticals, particularly in the development of compounds that have therapeutic applications.

Latest Patents

Hiratsuka holds a patent for "Phenylethanolamine compounds useful as .beta. 3 agonists, process for." This innovation highlights his expertise in creating compounds that can potentially improve health outcomes.

Career Highlights

He is currently associated with Mitsubishi-Tokyo Pharmaceuticals, Inc., where he continues to work on groundbreaking pharmaceutical research. His work has been instrumental in advancing the understanding and application of beta-3 agonists.

Collaborations

Hiratsuka has collaborated with notable colleagues, including Susumu Tsuchiya and Nobuyuki Yasuda. These partnerships have fostered a collaborative environment that enhances innovation and research in their field.

Conclusion

Kozo Hiratsuka's contributions to pharmaceutical innovations underscore his role as a key inventor in the industry. His work continues to influence the development of new therapeutic compounds.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…